News by community
20.11.2019 GNUbiotics Sciences announces a strategic agreement with Evonik Nutrition & Care to manufacture GNUbiotics’ Animal Milk Oligosaccharide, AMObiome™
First-in-class Animal Milk Oligosaccharide AMObiome™ to respond to the increasing demand for natural break-through products for companion and production animal health.
Lausanne, Switzerland, November 20, 2019 – Evonik Nutrition & Care and GNUbiotics Sciences SA today announced that they have entered into an agreement under which Evonik will manufacture AMObiome™, a critical missing nutritional component that restores natural symbiosis in pets and livestock animals with microbiota imbalance.
This strategic partnership underlines the benefits of a startup company with an innovative technology partnering with a CMO leader with the right competencies and assets to streamline the path towards commercial launch of the highest quality product.
“At GNUbiotics, we’re passionate about translating innovation into benefits for companion and production animals. AMObiome™ is first in class product to restore animal microbiota naturally” said Jean-Philippe Kunz, CEO at GNUbiotics.
Pre-clinical studies of AMObiome™ have shown the selective promotion of key commensal microbes such as Lactobacillus spp, Akkermansia spp, Bacteriodes spp and Megamonas while intelligently moderating potential pathogens such as E. coli and Salmonella.
With the first commercial lots successfully manufactured by Evonik, GNUbiotics has initiated two clinical trials with AMObiome™ in cats and dogs known as RESILIENT1 and MOTIVATE1 that are based on guidelines set by the Association of American Feed Control Officials (AAFCO). These trials plus those in partnerships involve up to 300 animals.
“We are excited about the partnership with Evonik as it allows us to manufacture our novel AMO to the highest production standards as we begin commercialization” said Yemi Adesokan, CSO at GNUbiotics .
“We are pleased to support GNUbiotics by applying our technical expertise and industrial capabilities to enable the scale up and commercialization of AMObiome™.” said, Dr. Jean-Luc Herbeaux, SVP and General Manager of the Evonik business line Health Care. “As a market leading CDMO in pharma and food ingredients, Evonik is committed to supporting customers of all sizes in industrializing their technologies.”
GNUbiotics is a Swiss based commercial biotech startup founded to develop a platform to commercialize breakthrough ingredients for the functional nutrition markets.
The complex formulations exhibit the natural diversity, complexity and sialylation of these unique structures found in mammalian mothers’ milk. Milk oligosaccharides are crucial for balanced growth, protection against infections, post-antibiotic recovery and immune development.
Evonik is one of the world leaders in specialty chemicals. In fiscal 2018, the enterprise with more than 32,000 employees generated sales of €13.3 billion and an operating profit (adjusted EBITDA) of €2.15 billion from continuing operations. The Nutrition & Care segment produces specialty chemicals, principally for use in consumer goods for daily needs, and in animal nutrition and healthcare products.
AMObiome™ is a patented complex and diverse AMO containing over 30 oligosaccharide species that support the Development, Protection and Restoration of the microbiome of pets and production animals.